MANGOCEUTICALS INC.NEW Aktie Logo
US56270V2051
A40RA3

MANGOCEUTICALS INC.NEW Aktie

Cargando cotizaciones...

Previsión

No hay datos de analistas disponibles para esta empresa.


  • Mangoceuticals announces merger with nuclear technology company Nuclea

    Mangoceuticals has entered into a definitive combination agreement with Nuclea Energy under which a newly formed subsidiary will merge with Nuclea and the result will be an indirect wholly owned subsidiary of Mangoceuticals. Nuclea is developing the lead‑cooled, graphite‑moderated micro‑modular reactor Morpheus, with a power scale of roughly 3.5 MWe to 50 MWe, and envisages applications including data centers, defense facilities and remote communities. Nuclea shareholders will receive exchangeable subsidiary shares on a one‑for‑one basis, with their rights limited prior to closing to 19.99% of Mangoceuticals’ outstanding common shares; closing is subject to shareholder approval and NASDAQ/SEC approvals. » Más en de.investing.com


  • Mangoceuticals sues Clarity Ventures in Texas for over $73 million

    Mangoceuticals has filed a lawsuit against Clarity Ventures in a Texas court seeking more than $73 million plus interest, costs and attorneys’ fees. The company alleges Clarity failed to deliver a fully functional, HIPAA-compliant ERP and e-commerce platform; Clarity denies the claims and has filed a counterclaim over allegedly unpaid invoices. Mangoceuticals says it made all payments and has since developed its own in‑house telemedicine and e-commerce platform; the stock recently suffered a sharp decline and the company reported falling revenues (down 38% to $0.47 million) with a gross margin of 60.61%. » Más en de.investing.com


  • Mangoceuticals plans up to $100 million Solana treasury via subsidiary Mango DAT

    Mangoceuticals announced a treasury strategy to invest up to $100 million into the Solana blockchain through its newly formed subsidiary Mango DAT. The Cube Group has been appointed as asset manager; the target is staking yields of 7–8% annually with active management potential of 8–20%. To finance the plan the company intends to use its shelf registration; a successful sale of the securities is not guaranteed. Additionally, Mangoceuticals recently raised $2.5 million through a registered direct placement and is continuing to expand its telemedicine offerings after denying partnership claims with Novo Nordisk and Eli Lilly. » Más en de.investing.com

Datos financieros de la empresa

En el último trimestre, MANGOCEUTICALS INC.NEW Aktie tuvo unos ingresos de 60,25 mil € y un beneficio neto de -1,15 M €
(EUR) jun 2026
YoY
Ingresos 60,25 mil 57,76 %
Beneficio bruto 38,74 mil 49,23 %
Beneficio neto -1,15 M 74,97 %
EBITDA -672,42 mil 82,61 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
6 M €
Número de acciones
16,97 M
Máximo/mínimo de 52 semanas
2,37 € - 0,14 €
Dividendos No
Beta
2,10
Ratio P/E
-0,35
Ratio PEG
0,00
Ratio P/B
0,56
Ratio P/S
22,05

Perfil de la empresa

Nombre
MANGOCEUTICALS INC.NEW Aktie
CEO
Jacob D. Cohen
Empleados 3

Descubrir activos

Los accionistas de MANGOCEUTICALS INC.NEW Aktie también invierten en los siguientes activos

🍪

Parqet  usa cookies. Más información